Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Pipeline Review, H1 2016

  • ID: 3753876
  • Drug Pipelines
  • Region: Global
  • 53 pages
  • Global Markets Direct
1 of 5
Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Pipeline Review, H1 2016

Summary

‘Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Pipeline Review, H1 2016’, provides in depth analysis on Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted pipeline therapeutics.

The report provides comprehensive information on the Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166)
- The report reviews Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects
- The report assesses Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) Overview

Therapeutics Development

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Stage of Development

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Therapy Area

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Indication

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Companies

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Products under Development by Universities/Institutes

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Companies Involved in Therapeutics Development

Momenta Pharmaceuticals, Inc.

Progen Pharmaceuticals Limited

Sigma-Tau S.p.A.

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Drug Profiles

Antibodies to Inhibit Heparanase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit Heparanase for Lung Cancer and Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

necuparanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PG-545 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roneparstat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target Heparanase for Oncology, Immunology and Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Dormant Projects

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Discontinued Products

Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Featured News & Press Releases

Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer

May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting

Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives’ Patent

Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer

Oct 29, 2013: PG545 Phase 1 Cancer Trial Update

Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics

May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001

Jul 02, 2012: Momenta Pharma Doses First Patient With M402 In Phase I/II Clinical Trial In Metastatic Pancreatic Cancer

Jun 04, 2012: Momenta Pharma Presents Positive Preclinical Results Of M402 In Combination With Gemcitabine At ASCO 2012 Annual Meeting

May 30, 2012: Progen Pharma Obtains Australian Patent For Heparan Sulfate Mimetic Compounds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Momenta Pharmaceuticals, Inc., H1 2016

Pipeline by Progen Pharmaceuticals Limited, H1 2016

Pipeline by Sigma-Tau S.p.A., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Momenta Pharmaceuticals, Inc.
Progen Pharmaceuticals Limited
Sigma-Tau S.p.A.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll